Clinical Trial Update: Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab for schizophrenia spectrum disorders has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Region Örebro County | Conditions: Schizophrenia Spectrum and Other Psychotic Disorders, Treatment-resistant Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2025-03-21